1Q 2026 Financial Summary

SAR (mn)	1Q 2026	1Q 2025	YOY Δ%
Revenue	481.4	457.5	+5%
Gross profit	310.4	292.8	+6%
Operating profit	172.4	158.2	+9%
Net profit	168.2	157.0	+7%
EBITDA	186.7	172.4	+8%
FCF	180.5	156.6	+15%
EPS	2.4	2.2	+7%

 

JEDDAH, 23rd April 2026 – Jamjoom Pharmaceuticals Factory Co. (Ticker: 4015.SR) delivered stable Q1 2026 performance, despite operating in a broader declining market backdrop with revenue reaching SAR 481.4 million, EBITDA rising 8% to SAR 186.7 million with a margin expansion to 38.8%, and net profit increasing 7% to SAR 168.2 million with a net margin of 34.9%. Growth was driven by sustained demand for strategic brands, strengthened commercial execution, and improved operating leverage.

 

Tarek Hosni, CEO of Jamjoom Pharma, commented on the 1Q 2026 performance:

“Despite operating in a market that experienced an unexpected contraction and amid an environment of heightened geopolitical uncertainty, Jamjoom Pharma delivered a resilient and disciplined performance in the first quarter of 2026. The continued ability to grow ahead of the market underscores the strength, scalability, and defensiveness of our business model, as well as the commitment and excellence of our teams across all markets.

Net profit grew faster than revenue, reflecting effective cost discipline, enhanced operating leverage, and a clear focus on value-accretive growth. This performance reinforces our ability to navigate volatility while remaining firmly aligned with our long‑term strategic priorities.

Demand for our strategic brands remained robust, while the continued expansion of our cardiometabolic portfolio further strengthens its position as a key engine of sustainable growth. In parallel, our Consumer Health portfolio demonstrated solid resilience, despite a more cautious consumer environment.

Operationally, we have been tackling supply challenges through strategic safety stock to ensure business continuity and cost efficiency, while the Jeddah Sterile Facility continued to scale to support rising demand for high‑value sterile products. With a strong balance sheet and a clear roadmap for disciplined execution, Jamjoom Pharma remains well positioned to continue delivering calculated growth and long‑term value creation, even in a challenging external environment.”